IMMUNOTHERAPY WITH A POLYVALENT MELANOMA VACCINE PLUS BCG IN STAGE IV

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to determine whether Bacillus Calmette Guerin (BCG), a bovine tubercle germ in combination with melanoma vaccine (C-VAX) is more effective than BCG and a placebo in stimulation of an immune response against melanoma, in improving overall survival, and increasing a delay in recurrence following surgery. This research is being done because there is no currently approved treatment of melanoma, which prolongs the time to recurrence. It is hoped that C-VAX, an experimental vaccine, will have benefits, which will help alleviate this problem.